While the data presented are promising, botensilimab, balstilimab, and agenT-797 are currently investigational agents and have not been approved for therapeutic use in any jurisdiction. InvestingPro ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback